Cytek Biosciences Inc. (CTKB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.13 (-2.70% 1D, market cap $818.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #404 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.5% realized swing band)
Altman Z-Score 4.76 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CTKB currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.31) and Max Pain ($6.44) forces dealer call-delta covering toward $6.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cytek Biosciences Inc. (CTKB) dropped -2.70% to $6.13, trading at 93% of its 52-week range ($3.31 – $6.34). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conference
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CTKB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CTKB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytek Biosciences Inc. (CTKB) ranks #404 by composite RQD confidence (45/100, grade D) and #384 by equity capitalization ($818.9M). Within this direct 5-issuer industry benchmark cohort, CTKB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CTKB at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTKB
ACTIVE
Cytek Biosciences Inc. | D | 45/100 | — | 51.8% | -12.7% | -2.70% | $818.9M | Benchmark Subject |
| PACB Pacific Biosciences of California Inc. | D | 44/100 | — | 28.6% | -35.0% | -10.17% | $901.4M | /pacb-vs-ctkb → |
| NAUT Nautilus Biotechnology Inc. | D- | 43/100 | — | — | -35.0% | -13.06% | $399.9M | /naut-vs-ctkb → |
| ALMR Alamar Biosciences Inc. | C- | 61/100 | — | — | — | -10.11% | $2.36B | /almr-vs-ctkb → |
| LAB Standard BioTools Inc. | E | 27/100 | — | 49.9% | -28.7% | -1.61% | $244.7M | /lab-vs-ctkb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported GAAP revenue of $201.5M (+0.5% vs. FY2024 revenue of $200.5M , and +4.4% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$4.7M, and free cash flow of -$8.8M (-140.1% YoY). On the balance sheet, CTKB closed FY2025 with $461.5M in total assets against $0 in total debt (Altman Z-Score: 4.76, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $201.5M | -$66.5M | -$4.7M | -$8.8M | $461.5M | — |
| FY2024 (FY) | 2024-12-31 | $200.5M | -$6.0M | $25.4M | $21.9M | $499.5M | — |
| FY2023 (FY) | 2023-12-31 | $193.0M | -$12.1M | $5.3M | $5.3M | — | — |
As of 2026-11-02, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.13 (-2.70% 1D, market cap $818.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #404 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CTKB last traded at $6.13 (-2.70% on volume of 1,866,615 shares), positioning the stock +15.44% above its 50-day simple moving average ($5.31) and +31.55% above its 200-day simple moving average ($4.66). Across its 52-week range of $3.31 to $6.34, CTKB sits at the 93.1% percentile with a 14-day RSI of 68.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.5% ($5.43 to $6.83).
Why CTKB Stock dropped -2.70% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CTKB scores 45 out of 100 for a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Taken together, the rating frames CTKB as a name where the present operating picture is weak, with the main support coming from institutional positioning rather than fundamentals or insider behavior. The price-to-value tradeoff is that a stock with negative ROIC and negative free cash flow yield depends on a turnaround in profitability that the source data does not yet show. Upside would need evidence of margin repair; without it, the rating points to continued distribution risk.
Cytek Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Per the company profile, it has a market capitalization of $0.8B. The source data does not describe its specific products, customer base, or revenue model beyond the sector and industry classification. Per the financials, FY 2025 revenue was $201.5M.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $201.5M | $-40.4M | $-66.5M | N/A | $-8.8M | $90.9M | N/A |
| FY 2024 | $200.5M | $-20.5M | $-6.0M | N/A | $21.9M | $98.7M | N/A |
| FY 2023 | $193.0M | $-27.8M | $-12.1M | N/A | $5.3M | N/A | N/A |
Per the market data, the company reports a gross margin of 51.8%, an operating margin of -20%, and a net margin of -33%. ROIC is -12.7%. Per the RQD rating, the Altman Z-Score is 4.76 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Revenue has been broadly flat across the three periods, while net income deteriorated sharply in FY 2025 to $-66.5M. Cash declined from $98.7M to $90.9M over the latest year.
Per the recent news feed, the catalysts are largely routine: multiple market-wire items on CTKB estimates and market action, a stock-analysis item describing a "modest fair value lift" as analysts weigh profitability, and a Yahoo Finance item noting analysts estimate a decline in earnings. Also per the feed, the company will report Q3 2026 financial results on November 4, 2026, and a CEO and CFO will join a November 17 fireside chat with a live webcast. All news items carry a YELLOW light and MARKET WIRE impact label. The earnings-decline estimate is the most material risk item in the feed. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Cytek Biosciences Inc. (CTKB) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.
Welcome to the CTKB (Cytek Biosciences Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CTKB, but look at what you are paying: current EV/EBITDA multiples with 51.8% gross margins. Unless Cytek Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CTKB, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $6.30 (52-wk range $3.31 - $6.34), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).